The phrase "use it or lose it" has followed men's sexual health around for decades, usually as locker-room folklore rather than clinical guidance. But the relationship between sexual frequency and erectile dysfunction has been studied in population cohorts, in tissue biology, and in post-surgical rehabilitation protocols — and the accumulated evidence points in a consistent direction. Erections are not merely the output of penile health. They appear to be part of the maintenance system that preserves it.
Understanding why requires stepping away from the psychology of libido and into the mechanics of oxygen delivery. The penis spends the overwhelming majority of each day in a flaccid, low-oxygen state. Erections — nocturnal, spontaneous, or sexual — are the intervals during which that tissue is flooded with oxygenated arterial blood. What happens in the absence of those intervals is where the clinical interest lies.
The Tampere Cohort: Frequency Predicted Future Risk
The most frequently cited evidence on sexual frequency and erectile dysfunction comes from the Tampere Aging Male Urologic Study, a population-based Finnish cohort. Investigators followed 989 men aged 55 to 75 who had no erectile dysfunction at baseline, assessed with the validated five-item International Index of Erectile Function, and re-surveyed them five years later [1].
The gradient they found was steep. Men reporting intercourse less than once per week had an incidence of moderate or complete erectile dysfunction of 79 cases per 1,000 person-years. At once per week, incidence fell to 32 per 1,000. At three or more times per week, it fell again to 16 per 1,000. After adjustment for age, hypertension, heart disease, diabetes, cerebrovascular disease, depression, body mass index, and smoking, men in the least-frequent group still carried roughly twice the incidence of those reporting weekly intercourse (incidence rate ratio 2.2, 95% CI 1.3–3.8) [1].
Two caveats deserve emphasis. First, this is observational data, and reverse causation is a genuine concern: men with early, subclinical erectile decline may simply have less sex, making low frequency a marker of a problem already underway rather than a cause of one. Second, the study did not ask about masturbation, so "frequency" here means partnered intercourse specifically. The authors' own framing was cautious — they concluded that continued sexual activity is associated with lower erectile dysfunction incidence in proportion to coital frequency, and that clinicians should support patients' sexual activity rather than treat it as optional.
Why Oxygen Is the Proposed Mechanism
The biological rationale is better established than the epidemiology. Oxygen tension inside the corpus cavernosum is genuinely low at rest. In men with normal erectile function, flaccid-state partial pressure of oxygen sits around 25–40 mmHg. During an erection, arterialized inflow raises it to roughly 90–100 mmHg [2,3]. Direct spectroscopic measurement confirms the shift: corporal oxygen saturation measured approximately 45–53% in the flaccid state versus 77–80% in the erect state, and men with erectile dysfunction showed significantly lower flaccid corporal saturation than men without [3].
That oxygen swing is not incidental. It is a regulatory signal. Nitric oxide synthase activity — the enzymatic step that initiates the entire erectile cascade — is oxygen-dependent, and low oxygen tension suppresses nitric oxide release in cavernosal tissue even when nerves and endothelium are otherwise intact [3]. Prostaglandin E1 synthesis, which restrains collagen deposition, is similarly oxygen-dependent [2].
Conversely, sustained hypoxia upregulates transforming growth factor beta-1 (TGF-β1), a cytokine that drives collagen synthesis in human cavernosal smooth muscle cells in culture [2,4]. The corpus cavernosum depends on a specific ratio of smooth muscle to connective tissue to perform veno-occlusion — the trapping of blood that sustains rigidity. As collagen accumulates and smooth muscle content falls, that trapping mechanism degrades, producing corporal veno-occlusive dysfunction. This is one of the mechanisms behind venous leak, and it is structural rather than purely functional, which is why it tends not to reverse on its own.
The Rat Neurotomy Model: Removing Erections Deliberately
Human observational data cannot separate cause from consequence, but animal work can. In a widely referenced experiment, investigators severed the cavernous nerves in rats — eliminating the neural pathway that produces spontaneous and nocturnal erections — and examined the tissue three months later [4].
The neurotomy group showed significantly elevated hypoxia-inducible factor 1-alpha, confirming that the tissue was in fact hypoxic, alongside significantly increased TGF-β1 messenger RNA and protein and increased collagen III deposition [4]. The causal chain the model demonstrates is direct: remove erections, and the tissue becomes hypoxic; hypoxia induces profibrotic signaling; fibrosis follows. The authors explicitly suggested that cavernous fibrosis might be reduced by interventions that increase corporal oxygenation during the at-risk period.
That suggestion became clinical practice. Penile rehabilitation protocols after radical prostatectomy exist precisely because post-surgical neuropraxia abolishes nocturnal erections, producing persistent cavernosal hypoxia, smooth muscle apoptosis, and degeneration [5]. Men with normal function experience roughly three to five nocturnal erections nightly, each lasting 30–45 minutes — a cumulative 1.5 to 3 hours of high-oxygen exposure per night [5]. Rehabilitation strategies are attempts to replace that lost exposure by other means.
What This Implies for Men Without Surgery
Radical prostatectomy is an abrupt, total loss of nocturnal erections. Most men experience something slower and less obvious. Vascular aging, hypertension, dyslipidemia, diabetes, and sleep disruption each reduce the frequency and rigidity of spontaneous erections gradually, over years. If the hypoxia-fibrosis model holds, that gradual reduction is not just a symptom accumulating — it is a mechanism compounding.
This reframes what early erectile dysfunction represents. A man in his late forties who notices erections becoming less reliable is often watching two processes at once: the vascular condition that reduced the erections, and the tissue remodeling that reduced erections then accelerate. Which is why erectile dysfunction is rarely a static complaint. Left unaddressed, the trajectory tends to be downward, and part of that downward slope is potentially modifiable.
It is worth stating plainly what the evidence does not support. No study demonstrates that increasing intercourse frequency reverses established erectile dysfunction. The Tampere data describe incidence in men who started without the condition [1]. The tissue biology describes a plausible mechanism, not a proven clinical intervention. "Have more sex" is not a prescription, and framing it that way risks adding performance pressure to men who are already anxious about performance.
Pharmacologic Approaches to Corporal Oxygenation
If the target is time-under-oxygenation rather than any single sexual encounter, dosing schedule becomes clinically interesting. On-demand PDE5 inhibitors produce a discrete window of enhanced response around a planned encounter. Daily low-dose regimens produce continuous circulating drug levels and a lower barrier to spontaneous erectile events.
In a randomized crossover study comparing chronic daily tadalafil against on-demand dosing in men with erectile dysfunction, chronic administration — but not on-demand use — improved flow-mediated dilation and peak systolic velocity of the cavernous arteries, with improvements maintained two weeks after discontinuation [6]. The chronic arm also produced a marked increase in morning erections. The investigators argued this determines better penile oxygenation and provides a rationale for vascular rehabilitation [6]. A twelve-month observational study of daily tadalafil 5 mg in men with benign prostatic hyperplasia similarly reported improved brachial-ankle pulse wave velocity from three months onward, alongside improved erectile function scores [7].
The evidence is not uniform. A double-blind randomized trial in younger men without comorbidities found that four weeks of low-dose daily tadalafil improved erectile function scores and flow-mediated dilation no more than placebo did, with substantial placebo response in both arms [8]. The signal appears strongest in men who have measurable vascular impairment to begin with, and weakest in men who do not — which is consistent with a rehabilitation mechanism rather than a general enhancement effect.
Conclusion
The link between sexual frequency and erectile dysfunction is better understood as a link between erection frequency and tissue oxygenation. Erections deliver oxygen; oxygen suppresses the profibrotic signaling that degrades the smooth muscle architecture erections depend on. Population data show a dose-dependent inverse association between coital frequency and future erectile dysfunction incidence [1]. Tissue and animal work supply a coherent mechanism [2,3,4]. Rehabilitation medicine already treats that mechanism as actionable after prostate surgery [5].
For men outside that surgical context, the practical implication is not a frequency quota. It is that declining erections warrant earlier clinical attention than most men give them, because the decline may be self-reinforcing. Evaluation should address the underlying vascular and metabolic drivers — blood pressure, glucose, lipids, sleep, and activity — rather than symptoms alone. Anyone considering pharmacologic support should discuss dosing strategy with a physician, since daily and on-demand regimens differ in more than convenience.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. Their daily formulation, EPIQ CHEWS, combines low-dose tadalafil and vardenafil with vitamin D3 and K2 in a once-daily chewable, and further reading on men's vascular health is available on the OnyxMD blog.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Koskimäki J, Shiri R, Tammela T, Häkkinen J, Hakama M, Auvinen A. Regular intercourse protects against erectile dysfunction: Tampere Aging Male Urologic Study. The American Journal of Medicine. 2008;121(7):592-596. doi:10.1016/j.amjmed.2008.02.042
Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. International Journal of Impotence Research. 1998;10(2):113-120. doi:10.1038/sj.ijir.3900328
Padmanabhan P, McCullough AR. Penile oxygen saturation in the flaccid and erect penis in men with and without erectile dysfunction. Journal of Andrology. 2007;28(2):223-228. doi:10.2164/jandrol.106.001313
Leungwattanakij S, Bivalacqua TJ, Usta MF, et al. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. Journal of Andrology. 2003;24(2):239-245. doi:10.1002/j.1939-4640.2003.tb02668.x
Qian SQ, Gao L, Wei Q, Yuan J. Vacuum therapy in penile rehabilitation after radical prostatectomy: review of hemodynamic and antihypoxic evidence. Asian Journal of Andrology. 2016;18(3):446-451. doi:10.4103/1008-682X.159716
Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. International Journal of Impotence Research. 2007;19(2):200-207. doi:10.1038/sj.ijir.3901513
Amano T, Earle C, Imao T, Matsumoto Y, Kishikage T. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. The Aging Male. 2018;21(1):77-82. doi:10.1080/13685538.2017.1367922
Pattanaik S, Kaundal P, Mavuduru RS, Singh SK, Mandal AK. Endothelial dysfunction in patients with erectile dysfunction: a double-blind, randomized-control trial using tadalafil. Sexual Medicine. 2019;7(1):41-47. doi:10.1016/j.esxm.2018.11.008
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.